Compare APLT & AWF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APLT | AWF |
|---|---|---|
| Founded | 2016 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.1M | 924.4M |
| IPO Year | 2019 | N/A |
| Metric | APLT | AWF |
|---|---|---|
| Price | $0.12 | $10.67 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $1.25 | N/A |
| AVG Volume (30 Days) | ★ 9.3M | 190.0K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.57% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,000,000.00 | N/A |
| Revenue This Year | $124.18 | N/A |
| Revenue Next Year | $66.67 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.10 | $9.20 |
| 52 Week High | $1.50 | $10.67 |
| Indicator | APLT | AWF |
|---|---|---|
| Relative Strength Index (RSI) | 26.58 | 40.42 |
| Support Level | $0.10 | $10.53 |
| Resistance Level | $0.26 | $10.71 |
| Average True Range (ATR) | 0.02 | 0.07 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 15.57 | 25.20 |
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
Alliancebernstein Glb High Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its primary investment objective is to seek high current income, and secondarily, capital appreciation. The fund invests in debt securities, including Sovereign Debt Obligations and corporate debt, denominated in non-U.S. currencies as well as in the U.S. Dollar. It may invest without limit in emerging and developed markets and debt securities of U.S. and non-U.S. corporate issuers.